ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026
Comparison of KONAR-multifunctional occluder and Amplatzer occluders in transcatheter closure of patent arterial ducts and ventricular septal defects.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter closure of patent ductus arteriosus (PDA) and ventricular septal defect (VSD) is performed using various occluder devices.
objectiveWe aim to compare the use of KONAR-Multifunctional Occluder (KONAR-MFO) and Amplatzer occluders (ADO-I, ADO-II) for closure of PDAs and VSDs.
methodsThis is a retrospective study on patients who underwent transcatheter PDA or VSD closure between June 2023 and October 2025. Patients were categorized according to the occlusion device and the underlying defect. Data were analysed comprehensively.
resultsThe study included 173 patients; 116 (67.1%) and 57 (32.9%) underwent PDA and VSD closure, respectively, using 99 ADO-I, 53 KONAR-MFO, and 21 ADO-II devices. The KONAR-MFO was used in smaller, younger patients, and the ADO-I in heavier, older patients (p < 0.05). The ADO-I was used for PDA type-A (40.4%), type-E (12.1%), type-C and D (9.1% for each), as well as perimembranous and muscular VSDs (13.1% each). The KONAR-MFO was used for peri-membranous VSDs (47.2%), Gerbode-type VSDs (5.7%), and PDA type-B (14.1%). The ADO-II was employed for PDA type-E (57.1%) and type-C (42.9%), without use in VSDs. The KONAR-MFO and ADO-II devices showed the shortest procedural and fluoroscopy times with the lowest contrast use, owing to single-access deployment without arteriovenous loop formation. Freedom from all types of complications was 73.9%, 71.1%, and 66.7% for KONAR-MFO, ADO-I, and ADO-II, respectively. In ADO-I, residual shunt, device embolization, and complete heart block occurred in 2.0% each. In KONAR-MFO, left pulmonary artery (LPA) stenosis and mild aortic regurgitation were observed in 3.8% each, while residual shunt and device embolization were observed in 1.9%. ADO-II was associated with the highest residual shunt and device embolization, both occurring at 9.5%.
conclusionsADO-I was used to close PDA and VSD, with longer procedural times. KONAR-MFO offered useful applications across complex VSDs with safety profiles in smaller, younger patients. ADO-II was preferred for tubular and elongated PDAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.